The American College of Cardiology (ACC) has announced the late-breaking clinical trials schedule for its 66th annual scientific session & expo.
The conference takes place from March 17 to March 19 at the Walter E. Washington Convention Center in Washington, D.C.
Here is a list of the late-breaking sessions (all times are Eastern Standard Time):
Friday, March 17
Title: ACC.17 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials
Room: Main Tent, Hall D
Time: 8:00 a.m. to 10:00 a.m.
* FOURIER: Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
* SPIRE 1 and SPIRE 2: Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High Risk Patients
* SURTAVI: Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis Compared With Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk: First Results From the SURTAVI Clinical Trial
Friday, March 17
Title: Featured Clinical Research I
Room: 146B
Time: 12:15 p.m. to 1:45 p.m.
* RESET-HCM: Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy
* S2P Study: Results of MRI-Based Screening Study of 5130 Candidates for Sports Participation
* MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease
* Effects of Different Front-of-Pack Food Labelling Formats on the Healthiness of Food Purchases — a Randomized Trial
* Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported
* ORION 1: LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial
Saturday, March 18
Title: Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Room: Main Tent, Hall D
Time: 8:00 a.m. to 9:15 a.m.
* EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
* GEMINI-ACS-1: A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes
* REACH: e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial
* CARAT: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study
* EBBINGHAUS: Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial
Saturday, March 18
Title: Late-Breaking Clinical Trials
Room: Main Tent, Hall D
Time: 10:45 a.m. to 12:00 p.m.
* COMPARE-ACUTE: FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease
* DEFINE-FLAIR: Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization
* IFR-SWEDEHEART: Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial
* DECISION CTO: Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial
* ABSORB III: Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Disease: Two-Year Outcomes From the ABSORB III Trial
Saturday, March 18
Title: Featured Interventional Clinical Research II
Room: 201
Time: 12:30 p.m. to 1:45 p.m.
* ADVICE Study: Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis from Two US Registries Linked to Medicare Data
* STS/ACC TVT Registry: Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry
* Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis
* RAD Matrix: Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study
* Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States
Sunday, March 19
Title: Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Room: Main Tent, Hall D
Time: 8:00 a.m. to 9:15 a.m.
* LEVO-CTS: Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial
* Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network
* Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort
* RESOLVE and SAVORY: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries
* VISION Study: Relationship Between High Sensitive Troponin T Measurements and 30-Day Mortality After Noncardiac Surgery
Sunday, March 19
Title: Late-Breaking Clinical Trials
Room: Main Tent, Hall D
Time: 10:45 a.m. to 12:00 p.m.
* RE-CIRCUIT: Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study
* ARISTOTLE: Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
* Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database
* GIFT of Warfarin: Benefit of Pharmacogenetic Dosing
* SPAIN Study: Randomized Placebo Controlled Trial of Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope
Sunday, March 19
Title: Featured Clinical Research III
Room: 150A
Time: 2:00 p.m. to 3:30 p.m.
* Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled
* STOMP: The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function
* Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella
* CVD-REAL Study: Lower Rates of Hospitalization for Heart Failure in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs — Real-World Data From Four Countries and More Than 360,000 Patients: The CVD-REAL Study
* Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction
* Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the ‘Real World’
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.